Caracterización clínica y epidemiológica de la enfermedad renal poliquística en un Centro de referencia de Cuarto Nivel del Caribe Colombiano (2008-2022)
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.contributor.author | Dulce Muñoz, Jaime | |
| dc.contributor.author | Aroca Martínez, Gustavo | |
| dc.contributor.author | Depine, Santos | |
| dc.contributor.author | Correa Monterrosa, Mileidy | |
| dc.contributor.author | Álvarez Mora, Lisseth | |
| dc.date.accessioned | 2024-03-11T16:48:20Z | |
| dc.date.available | 2024-03-11T16:48:20Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Objetivo: La enfermedad renal poliquística (ERP) es una enfermedad autosómica dominante causada por la mutación principalmente de los genes PKD1 y PKD2, y la formación de quistes progresivos en el tiempo. Este estudio caracteriza los aspectos clínicos y epidemiológicos de pacientes con ERP atendidos en un centro de referencia. Métodos: Estudio de corte trasversal retrospectivo. Se obtuvo 54 registros de pacientes con ERP. Se analizaron datos demográficos, clínicos, bioquímicos, imagenológicos y terapéuticos mediante el uso del software (SPSS 23). Resultados: La edad media fue 56,9±12,8 años, el promedio de edad al diagnóstico 48,2 años; sexo predominante masculino (61 %). El síntoma clínico más frecuente el dolor abdominal (31 %); la manifestación extrarrenal más encontrada fue la poliquistosis hepática (24 %); el estadio renal II fue el más común (24 %), el antecedente predominante fue la HTA (26 %). Presentaron antecedente de ERP (16 %); el tratamiento habitual fue ARA II (34 %). 24 % de los pacientes recibieron terapia de remplazo renal. Conclusiones: La ERP afecta principalmente a personas de 56 años, predominio masculino. Entre los hallazgos clínicos se encuentra el dolor abdominal; las manifestaciones extrarrenales más frecuentes: poliquistosis hepática, hernias y la enfermedad diverticular; la HTA constituye el antecedente más frecuente. La hemodiálisis fue la modalidad sustitutiva más usada. | spa |
| dc.description.abstract | Objective: Polycystic kidney disease (PKD) is characterized by mutations in PKD1 and PKD2 and progressive cyst formation over time. This study characterized the clinical and epidemiological aspects of patients with PKD treated at a reference center. Methods: Retrospective cross-sectional study. We obtained 54 records from patients with PKD. Demographic, clinical, biochemical, imaging and therapeutic data were analyzed with the software (SPSS 23). Results: The mean age was 56.9±12.8 years, and the mean age at diagnosis was 48.2 years, predominantly male (61 %). The most frequent clinical symptom was abdominal pain (31 %); polycystic liver disease (24 %) was the most common extrarenal manifestation; renal stage II was the most common (24 %); and the predominant antecedent was hypertension (26 %). 16 % of the patients had a history of PKD (16 %), the usual treatment was ARB II (34 %). 24 % of the patients received renal replacement therapy. Conclusions: PKD mainly affects 56-year-olds, predominantly male. Clinical findings include abdominal pain. The most frequent extrarenal manifestations are polycystic liver disease, hernias, and diverticular disease; HTA is the most frequent antecedent. Hemodialysis is the most used replacement modality. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.doi | 10.47307/GMC.2024.132.1.8 | |
| dc.identifier.issn | 27390012 (Electrónico) | |
| dc.identifier.issn | 03674762 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/14318 | |
| dc.identifier.url | http://saber.ucv.ve/ojs/index.php/rev_gmc/article/view/27979 | |
| dc.publisher | ACADEMIA NACIONAL DE MEDICINA | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.source | Gaceta médica de Caracas | spa |
| dc.source | Gac Méd Caracas | eng |
| dc.source | Vol. 132 No. (1), (2024) | |
| dc.subject | Enfermedad renal poliquística | spa |
| dc.subject | Enfermedad renal crónica | spa |
| dc.subject | Quiste renal | spa |
| dc.subject | Polycystic kidney disease | eng |
| dc.subject | Chronic Kidney Disease | eng |
| dc.subject | Renal cyst | eng |
| dc.title | Caracterización clínica y epidemiológica de la enfermedad renal poliquística en un Centro de referencia de Cuarto Nivel del Caribe Colombiano (2008-2022) | spa |
| dc.title.translated | Clinical and epidemiological characterization of polycystic kidney disease in a Fourth-Level reference Center in the Colombian Caribbean (2008-2022) | eng |
| dc.type.driver | info:eu-repo/semantics/article | spa |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Colbert G, Elrggal M, Gaur L, Lerma E. Update and review of adult polycystic kidney disease. Diseasea- Month. 2020;66(5):100887. | eng |
| dcterms.references | Wilson P. Polycystic Kidney Disease. N Engl J Med. 2004;350(2):151-164. | eng |
| dcterms.references | Ars E, Bernis C, Fraga G, Furlano M, Martínez V, Martins J, et al. Documento de consenso de poliquistosis renal autosómica dominante del grupo de trabajo de enfermedades hereditarias de la Sociedad Española de Nefrología. Revisión 2020. Nefrología. 2022;42(4):367-389. | spa |
| dcterms.references | Xue C, Zhou C-C, Wu M, Mei C-L. The clinical manifestation and management of autosomal dominant polycystic kidney disease in China. Kidney Dis. 2016;2(3):111-119. | eng |
| dcterms.references | Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol. 2018;29(10):2593-2600. | eng |
| dcterms.references | Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393(10174):919-935. | eng |
| dcterms.references | McConnachie DJ, Stow JL, Mallett AJ. Ciliopathies and the Kidney: A Review. Am J Kidney Dis. 2021;77(3):410-419. | eng |
| dcterms.references | Montaña A, Patiño N, Larrate C, Zambrano FA, Martínez J, Lozano H, et al. Update on polycystic kidney disease. Rev Fac Med. 2018;66(1):107-116. | eng |
| dcterms.references | Xue C, Mei CL. Renal fibrosis: Mechanisms and therapies. In: Advances in Experimental Medicine and Biology. Singapore: Springer Singapore; 2019.p.81- 100. | eng |
| dcterms.references | Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009;5(4):221-228. | eng |
| dcterms.references | Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):173-180. | eng |
| dcterms.references | Seeger-Nukpezah T, Geynisman DM, Nikonova AS, Benzing T, Golemis EA. The hallmarks of cancer: Relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol. 2015;11(9):515-534. | eng |
| dcterms.references | Vasileva VY, Sultanova RF, Sudarikova AV, Ilatovskaya DV. Insights into the molecular mechanisms of polycystic kidney diseases. Front Physiol. 2021;12. | eng |
| dcterms.references | Harris PC, Torres VE. Polycystic Kidney Disease, Autosomal Dominant Summary. In: Adam M, Everman D, editors. Gene Reviews. Seattle: National Center for Biotechnology Information; 2022.p.1-44. | eng |
| dcterms.references | Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials. Curr Hypertens Rev. 2020;17(3):228-237. | eng |
| dcterms.references | Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003;64(3):1035- 1045. | eng |
| dcterms.references | Perumareddi P, Trelka DP. Autosomal Dominant Polycystic Kidney Disease. Prim Care - Clin Off Pract. 2020;47(4):673-689. | eng |
| dcterms.references | Willey C, Gauthier-Loiselle M, Cloutier M, Shi S, Maitland J, Stellhorn R, et al. Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States. Curr Med Res Opin. 2021;37(7):1155-1162. | eng |
| dcterms.references | Rastogi A, Ameen KM, Al-Baghdadi M, Shaffer K, Nobakht N, Kamgar M, et al. Autosomal dominant polycystic kidney disease: Updated perspectives. Ther Clin Risk Manag. 2019;15:1041-1052. | eng |
| dcterms.references | Suwabe T, Shukoor S, Chamberlain A. Epidemiology of autosomal dominant polycystic kidney disease in Olmsted County. Am Soc Nephrol. 2020;15:69-79. | eng |
| dcterms.references | Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Prim. 2018;4(1). | eng |
| dcterms.references | Zahid R, Akram M, Rafique E. Prevalence, risk factors and disease knowledge of polycystic kidney disease in Pakistan. Int J Immunopathol Pharmacol. 2020;34:1-11. | eng |
| dcterms.references | Uchiyama K, Mochizuki T, Shimada Y, Nishio S, Kataoka H, Mitobe M, et al. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: A prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD). Clin Exp Nephrol. 2021;25(9):970-980. | eng |
| dcterms.references | Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32(8):1356-1363. | eng |
| dcterms.references | Guatibonza YP, Rodríguez RE, Córdoba JP, Zarante I. Actualidad de la enfermedad renal poliquística. Univ Méd. 2012;54(1):53-68. | spa |
| dcterms.references | Depine SÁ, Aroca Martínez G. Desafiando a la inequidad de Latinoamérica. Desafiando a la inequidad de Latinoamérica. Barranquilla: Ediciones Universidad Simón Bolivar; 2018.p,118. | spa |
| dcterms.references | Depine S, Hinojosa M, Calle M. Enfermedad Renal Crónica en los países andinos 2022. En: Depine S, editor. Lima: ORAS CONHU; 2022.p.106. | spa |
| dcterms.references | Rico-Fontalvo J, Yama-Mosquera E, Robayo-García A, Aroca-Martínez G, Arango-Álvarez JJ, Barros- Camargo L, et al. Situación de la enfermedad renal crónica en Colombia. Nefrol Latinoam. 2022;19(2):79-87. | spa |
| dcterms.references | Pei Y, Hwang YH, Conklin J, Sundsbak JL, Heyer CM, Chan W, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2015;26(3):746-753. | eng |
| dcterms.references | Schrier RW, Abebe K, Perrone RD. Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2015;372(10):975-977. | eng |
| dcterms.references | Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Philip Miller J, et al. The HALT polycystic kidney disease trials: Design and implementation. Clin J Am Soc Nephrol. 2010;5(1):102-109. | eng |
| dcterms.references | Chebib FT, Torres VE. Recent advances in the management of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13(11):1765-1776. | eng |
| dcterms.references | Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. N Engl J Med. 2017;377(18):1765-1776. | eng |
| dcterms.references | Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in Later- Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017;377(20):1930-1942. | eng |
| dcterms.references | Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-2418. | eng |
| dcterms.references | Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458- 2470. | eng |
| dcterms.references | Torres VE, Gansevoort RT, Perrone RD, Chapman AB, Ouyang J, Lee J, et al. Tolvaptan in ADPKD Patients With Very Low Kidney Function. Kidney Int Reports. 2021;6(8):217-218. | eng |
| dcterms.references | Blair HA. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs. 2019;79(3):303-313. | eng |
| dcterms.references | Chebib FT, Torres VE. Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for diseasemodifying therapy. Am J Kidney Dis. 2021;78(2):282- 292. | eng |
| dcterms.references | Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):830-840. | eng |
| dcterms.references | Park H, Paek JH, Kim Y, Park WY, Han S, Jin K. Clinical characteristics and risk factors for kidney failure in patients with autosomal dominant polycystic kidney disease: A retrospective study. Med (United States). 2022;101(47):E31838. | eng |
| dcterms.references | Torres V, Grantham JJ, Chapman AB, Mrug M. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:640-647. | eng |
| dcterms.references | Okyere P, Ephraim RKD, Okyere I, Attakorah J, Serwaa D, Essuman G, et al. Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana. BMC Nephrol. 2021;22(1):1-8. | eng |
| dcterms.references | Yu A, Chertow G, Luyckx V, Marsden P. Skorecky K, Taal M. Brenner y Rector. El riñón. 11th edición. España: Elsevier; 2021:2904. | eng |
| dcterms.references | Chen D, Ma Y, Wang X, Yu S, Li L, Dai B, et al. Clinical characteristics and disease predictors of a large chinese cohort of patients with autosomal dominant polycystic kidney disease. Kidney Disease. PLoS One 2014;9(3): e92232. | eng |
| dcterms.references | Ghata J, Cowley BD. Polycystic kidney disease. Compr Physiol. 2017;7(3):945-975 | eng |
| dcterms.references | Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011;57(5):692-699. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- 08. Muñoz J (76-88) (2).pdf
- Tamaño:
- 338.24 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 381 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: